ProPhase Labs, Inc. (PRPH) Insider Trading Activity

NASDAQ$0.372
Market Cap
$15.45M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
735 of 863
Rank in Industry
43 of 52

PRPH Insider Trading Activity

PRPH Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
–
Sells
$0
0
–

Related Transactions

About ProPhase Labs, Inc.

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Insider Activity of ProPhase Labs, Inc.

Over the last 12 months, insiders at ProPhase Labs, Inc. have bought $0 and sold $0 worth of ProPhase Labs, Inc. stock.

On average, over the past 5 years, insiders at ProPhase Labs, Inc. have bought $157,047 and sold $137,500 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 721 shares for transaction amount of $4,672 was made by Barr Jason Michael (director) on 2022‑03‑10.

List of Insider Buy and Sell Transactions, ProPhase Labs, Inc.

2022-03-10PurchaseBarr Jason Michaeldirector
721
0.0046%
$6.48
$4,672
+59.75%
2021-06-03PurchaseKarkus Ted WilliamCEO & CHAIRMAN
33,943
0.2283%
$5.07
$171,921
+35.81%
2020-08-13SaleKarkus Ted WilliamCEO & CHAIRMAN
50,000
0.4309%
$2.75
$137,500
+144.21%
2020-08-13PurchaseGLECKEL LOUIS MDdirector
50,000
0.4309%
$2.75
$137,500
+144.21%
2020-03-26SaleKarkus Ted WilliamCEO & CHAIRMAN
100,000
0.8634%
$1.75
$175,000
-1.63%
2020-03-26PurchaseGLECKEL LOUIS MDdirector
100,000
0.8634%
$1.75
$175,000
-1.63%
2019-10-01PurchaseBarr Jason Michaeldirector
2,870
0.0247%
$1.96
$5,625
-2.61%
2019-08-15PurchaseBarr Jason Michaeldirector
2,500
0.0226%
$2.05
$5,125
-0.33%
2019-08-14PurchaseBarr Jason Michaeldirector
6,000
0.0516%
$2.05
$12,300
-4.53%
2017-12-21SaleKarkus Ted WilliamCEO & CHAIRMAN
424,789
2.8532%
$2.30
$977,015
+82.05%
2017-09-29SaleKarkus Ted WilliamCEO & CHAIRMAN
364,950
2.4565%
$2.30
$839,385
+35.68%
2017-09-29SaleLeonard Braden Michael10 percent owner
1.7M
11.4114%
$2.30
$3.9M
+35.68%
2017-09-29SaleCUDDIHY ROBERT V JRChief Financial Officer
358,621
2.4139%
$2.30
$824,828
+35.68%
2017-09-29SaleBarr Jason Michaeldirector
4,379
0.0295%
$2.30
$10,072
+35.68%
2015-11-30PurchaseLeventhal Mark Sdirector
948
0.0059%
$1.48
$1,403
-2.60%
2015-11-27PurchaseLeventhal Mark Sdirector
13,300
0.0838%
$1.55
$20,615
-5.66%
2015-11-25PurchaseLeventhal Mark Sdirector
17,252
0.0956%
$1.30
$22,428
-1.32%
2015-11-24PurchaseLeventhal Mark Sdirector
18,500
0.1111%
$1.30
$24,050
+7.14%
2015-06-04PurchaseKarkus Ted WilliamSee Remarks
200,000
1.2581%
$1.30
$260,000
+8.03%
2015-05-19PurchaseKarkus Ted WilliamCEO & Chairman
399,008
2.5865%
$1.35
$538,661
+6.52%
Total: 68

Insider Historical Profitability

10.79%
QUIGLEY GUY J10 percent owner
2581559
6.2145%
$960,339.9505
Karkus Ted WilliamCEO & CHAIRMAN
2333471
5.6172%
$868,051.21114
+11.6%
PHILLIPS CHARLES AEVP, COO
1011706
2.4354%
$376,354.6304
Leventhal Mark Sdirector
881980
2.1231%
$328,096.5680
+8.87%
Leonard Braden Michael10 percent owner
627322
1.5101%
$233,363.78141
<0.0001%
Burnett Mark A.director
301768
0.7264%
$112,257.7020
GLECKEL LOUIS MDdirector
273840
0.6592%
$101,868.4820
+71.29%
CUDDIHY ROBERT V JRChief Financial Officer
132703
0.3194%
$49,365.5201
Frank Mark Shawndirector
70195
0.169%
$26,112.5410
+13.69%
Barr Jason Michaeldirector
30962
0.0745%
$11,517.8641
+59.75%
MCCUBBIN JAMES Tdirector
25937
0.0624%
$9,648.5610
0%
SCHAUM ROUNSEVELLE Wdirector
0
0%
$009

Historical Insider Profitability vs. Competitors

$2,051,022
1591
-12.84%
$58.05M
$22,899,264
81
34.90%
$17.46M
$218,350,131
64
16.68%
$221.98M
$125,860,243
57
-4.48%
$36.57M
$2,740,482
50
9.37%
$29.66M
$30,209,812
45
-1.91%
$13.31M
ProPhase Labs, Inc.
(PRPH)
$3,140,759
30
10.79%
$15.45M
$423,174,478
29
-7.58%
$38.46M
$32,539,771
28
33.37%
$230.33M
$25,034,841
20
9.38%
$119.7M
$934,616
12
74.76%
$8.2M
$758,061
9
60.03%
$167.73M
$4,039,981
8
-3.44%
$13.18M
$8,171,353
7
-14.29%
$14.31M
$138,873
5
1.23%
$65.14M
$15,894
5
-31.45%
$8.82M
$5,003,136
1
-14.58%
$284.35M
$999,999
1
-52.42%
$14.43M
$10,000
1
-96.58%
$6.93M

PRPH Institutional Investors: Active Positions

Increased Positions19+54.29%3M+116.02%
Decreased Positions13-37.14%500,910-20.71%
New Positions11New3MNew
Sold Out Positions5Sold Out182,856Sold Out
Total Postitions41+17.14%5M+95.31%

PRPH Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$217.001.56%655,032-915-0.14%2024-12-31
Renaissance Technologies Llc$95.000.68%286,485+71,375+33.18%2024-12-31
Hightower Advisors, Llc$78.000.56%236,781+57,736+32.25%2024-12-31
Sheets Smith Wealth Management$69.000.5%208,30000%2025-03-31
Geode Capital Management, Llc$67.000.49%203,528+42,793+26.62%2024-12-31
Perritt Capital Management Inc$63.000.45%190,000+107,068+129.1%2024-12-31
Warberg Asset Management Llc$34.000.24%101,672+101,672New2024-12-31
Cerity Partners Llc$31.000.22%94,113+94,113New2025-03-31
Chapin Davis, Inc.$26.000.19%80,000+30,000+60%2025-03-31
Blackrock, Inc.$23.000.16%68,859-783-1.12%2025-03-31

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.